Genprex secures $12.5M equity line with Lincoln Park; provides clinical trial updates

Genprex, Inc.

Entered purchase agreement for up to $12.5M in common stock; issued 1,186,859 commitment shares to Lincoln Park.
Acclaim-1 Phase 2a expansion targets ~33 patients; interim analysis of first 19 expected Q1 2026, top-line in H1 2026.
Acclaim-3 Phase 2 expansion plans ~50 patients; futility analysis after 25 patients expected Q1 2026.
Both Acclaim-1 and Acclaim-3 have FDA Fast Track designation; Acclaim-3 also has Orphan Drug Designation.
Proceeds from Lincoln Park sales to be used for working capital and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.